Autozhel' v kontrole biokhimicheskikh markerovaktivnosti akromegalii: predstavlenieklinicheskogo sluchaya
https://doi.org/10.14341/2071-8713-5088
Abstract
Acromegaly is a severe neuroendocrine disease that develops when the pituitary gland produces excess growth hormone (GH).
Acromegaly is not only a cosmetic problem. Hypersecretion of GH leads to variety complications, decreased quality of life, shortening
the expected lifespan due to development of severe cardiovascular complications. Timely diagnosis and adequate treatment can reduce
mortality by 2-5 times and medical therapy deservedly plays an important role in treatment of patients with acromegaly when radical
surgical treatment cannot be performed. We present a first Russian experience of acromegaly patient treatment with new preparation -
Somatulin Autogel, with analysis of its favorable effects on clinical and metabolic manifestations of the disease.
Acromegaly is not only a cosmetic problem. Hypersecretion of GH leads to variety complications, decreased quality of life, shortening
the expected lifespan due to development of severe cardiovascular complications. Timely diagnosis and adequate treatment can reduce
mortality by 2-5 times and medical therapy deservedly plays an important role in treatment of patients with acromegaly when radical
surgical treatment cannot be performed. We present a first Russian experience of acromegaly patient treatment with new preparation -
Somatulin Autogel, with analysis of its favorable effects on clinical and metabolic manifestations of the disease.
References
1. Акромегалия. Этиология, патогенез, клиника, диагностика, лечение. Под редакцией Дедова И. И., Мельниченко Г. А. Москва, 2009, 118.
2. Acromegaly - pathology, diagnosis and treatment // Taylor and Francis group, LLC. USA, 2005: 151.
3. Alexopoulou O., Abranis P., Verhelst J. Efficacy and tolerability of deep subcutaneous injections of lanreotide Autogel in acromegalic patients previously treated with octreotide Lar. // ENDO 2003. The Endocrine Society's 85th Annual Meeting June 19-22, Philadelphia.
4. Attanasio R., Lanzi R., Losa M. Effects of lanreotide Autogel on growth hormone, insulin-like growth factor 1, and tumor size in Acromegaly: a 1-year prospective multicenter study // Endocrine practice, 2008; 14(7): 846-855.
5. Auriemma R.S., Galdiero M., Grasso L.F., Vitale P., Cozzolino A., Lombardi G., Colao A., Pivonello R. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal // Eur J Endocrinol. 2010; 162(5): 993-9.
6. Bates A., Van`t Hoff W., Jones J. Does treatment of acromegaly affect life expectancy // Metabolism, 1995; 44: 1-5.
7. Beckers A. Does Preoperative Somatostatin Analog Treatment Improve Surgical Cure Rates in Acromegaly? A New Look at an Old Question // J Clin Endocrinol Metab, 2008; 93(8): 2975-2977.
8. Bevan J.S., Newell-Price J., Wass J.A., Atkin S.L., Bouloux P.M., Chapman J., Davis J.R., Howlett T.A., Randeva H.S., Stewart P.M., Viswanath A. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective // Clin Endocrinol (Oxf), 2008; 68(3): 343-9.
9. Brada M., Ashley S., Ford D. et al. Cerebrovascular mortality in patients with pituitary adenoma // Clinical Endocrinology, 2002; 57: 713-717.
10. Caron P. Lanreotide Autogel in acromegaly and neuroendocrine tumors // Therapy 2007; 4 (1): 9-29.
11. Chanson P., Borson-Chazot F., Kuhn J. et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly // Clinical Endocrinology 2008; 69: 299-305.
12. Croxtall J., Scott L. Lanreotide Autogel®. A Review of its Use in the Management of Acromegaly // Drugs, 2008; 68(5): 1-13.
13. Fahlbusch R., Buchfelder M., Kreutzer J. et al. Surgical management of acromegaly // Handbook of acromegaly/ed. J. Wass. Published by Bioscientifica, Brostol, UK, 2001: 41-47.
14. Giustina A., Chanson P., Bronstein M., Klibanski A. et al. A consensus on criteria for cure of acromegaly // Journal of Clinical Endocrinology and Metabolism, 2010: 95(7): 3141-3138.
15. Holdaway I., Rajasoorya C. Epidemiology of acromegaly // Pituitary 1999; 2(1): 29-41.
16. Lucas T., Astorga R. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial // Clinical Endocrinology, 2006; 65: 320-326.
17. Marianne Andersen. The role of lanreotide Autogel® in the treatment of acromegaly // Expert Rev. Endocrinol. Metab. 2007; 2(4): 433-441.
18. Melmed S., Casanueva F.F., Cavagnini F., et al. Guidelines for management // J Clin Endocrinol Metab, 2002; 87(9): 4054-8.
19. Muller A.F., van der Lely A.J. Pharmacological therapy for acromegaly: a critical review // Drugs, 2004; 64 (16): 1817-38.
20. Newman C.B., Melmed S., George A., et al. Octreotide as primary therapy for acromegaly // J Clin Endocrinol Metab, 1998; 83: 3034-40.
21. Pascale A. et al. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly // European Journal of Endocrinology, 2007; 157: 571-577.
22. Powell J.S., Wardlaw S.L., Post K.D., et al. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor-1 to define cure // J Clin Endocrinol Metab, 2000; 85: 2068-71.
23. Roberts B. New formulation helps nurses treat acromegaly // Practice Nursing 2002; 13(4): 179-181.
24. Ronchi C.L., Boschetti M., Degli Uberti E.C. Efficacy of a slow-release formulation of lanreotide (Autogel®120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study // Clin Endocrinol (Oxf), 2007; 67 (4): 512-9.
25. Somatuline Depot (lanreotide) injection US prescribing information. Paris: Tercica, 2007.
26. Tolis G., Angelopoulos N.G., Katounda E., et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs // Neuroendocrinology, 2006; 83 (3-4): 249-57.
Review
For citations:
, , , , Autozhel' v kontrole biokhimicheskikh markerovaktivnosti akromegalii: predstavlenieklinicheskogo sluchaya. Obesity and metabolism. 2010;7(4):44-47. (In Russ.) https://doi.org/10.14341/2071-8713-5088
Views:
466
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
